Markets:

Overview

News

Currencies

International

Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

29.08 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

July 27, 2023

During Thursday, 56 stocks hit new 52-week lows.

Via Benzinga

Nasdaq Up 1%; Meta Shares Surge Following Upbeat Results ↗

July 27, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.15% to 35,573.49 while the NASDAQ...

Via Benzinga

Why Mersana Therapeutics Stock Is Plunging Today? ↗

July 27, 2023

Mersana Therapeutics Inc (NASDAQ: MRSN) shares are sinking after the company announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did

Via Benzinga

What 4 Analyst Ratings Have To Say About Mersana Therapeutics ↗

June 16, 2023

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

May 24, 2023

Via Benzinga

FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death ↗

March 13, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Dow Jumps 100 Points; US GDP Rises 2.4% In Q2 ↗

July 27, 2023

U.S. stocks traded higher this morning, following the release of major economic reports on Thursday. Following the market opening Thursday, the Dow traded up 0.28% to 35,620.79 while the NASDAQ rose...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 27, 2023

Via Benzinga

Cancer Drug Trials Put On Hold After Patients Died ↗

June 17, 2023

Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023 ↗

June 16, 2023

Via Benzinga

NVIDIA To Rally Over 17%? Here Are 10 Other Analyst Forecasts For Friday ↗

June 16, 2023

Raymond James boosted the price target for Jabil Inc. (NYSE: JBL) from $100 to $120. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares rose 5% to close at $104.64 on...

Via Benzinga

Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results ↗

June 15, 2023

U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,...

Via Benzinga

Mersana's UpRi Shows Potential in Ovarian Cancer; Analyst Initiates Coverage with Buy Rating ↗

June 15, 2023

Guggenheim Partners has initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 15, 2023

Via Benzinga

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 15, 2023

Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.

Via Benzinga

Dow Surges Over 300 Points; Kroger Profit Beats Views ↗

June 15, 2023

U.S. stocks traded higher midway through trading, with Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.98% to 34,313.85 while the NASDAQ rose 0.73% to 13,726.16. The S&P 500,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

US Stocks Open Higher; Retail Sales Rise In May ↗

June 15, 2023

U.S. stocks traded higher this morning, with Dow Jones gaining around 180 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 34,159.59 while the NASDAQ rose 0.18% to...

Via Benzinga

Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser ↗

June 15, 2023

Markets gave back some ground after consideration of the Fed's latest interest rate decision.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 15, 2023

Via Benzinga

Why Are Mersana Therapeutics Shares Nosediving Today ↗

June 15, 2023

The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in

Via Benzinga

7 Stocks to Buy for 200% Returns This Year ↗

June 13, 2023

These high return stock investments all have the potential to triple in 2023 based on Wall Street expectations.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 03, 2023

Via Benzinga

US Stocks Edge Higher; AMD Shares Tank Despite Upbeat Results ↗

May 03, 2023

U.S. stocks traded up this morning, ahead of the Federal Reserve’s decision on an interest rate hike. Following the market opening Wednesday, the Dow traded up 0.05% to 33,700.93 while the NASDAQ rose...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗

January 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 03, 2023

Via Benzinga

Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗

December 23, 2022

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.